Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
10 Octubre 2024 - 7:00AM
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the
Company”), a clinical-stage biotechnology company developing novel
LAG-3 immunotherapies for cancer and autoimmune disease, today
announces Marc Voigt, CEO of Immutep, will participate in a
fireside chat at the Maxim Healthcare Virtual Summit on Wednesday,
October 16, 2024 at 9:30 am ET.
The fireside chat will be live on M-Vest. Click
here to reserve your seat.
About ImmutepImmutep is a
clinical stage biotechnology company developing novel LAG-3
immunotherapy for cancer and autoimmune disease. We are pioneers in
the understanding and advancement of therapeutics related to
Lymphocyte Activation Gene-3 (LAG-3), and our diversified product
portfolio harnesses its unique ability to stimulate or suppress the
immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to
maximise value for shareholders. For more information, please visit
www.immutep.com.
Australian
Investors/Media:Catherine Strong, Sodali & Co+61
(0)406 759 268; catherine.strong@sodali.com
U.S. Media:Chris Basta, VP,
Investor Relations and Corporate Communications+1 (631) 318 4000;
chris.basta@immutep.com
Immutep (NASDAQ:IMMP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Immutep (NASDAQ:IMMP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
